Resona Asset Management Co. Ltd. Has $16.36 Million Stock Position in Edwards Lifesciences Corporation $EW

Resona Asset Management Co. Ltd. boosted its position in Edwards Lifesciences Corporation (NYSE:EW) by 10.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 204,486 shares of the medical research company’s stock after acquiring an additional 19,802 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $16,355,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Resonant Capital Advisors LLC raised its position in shares of Edwards Lifesciences by 9.8% during the first quarter. Resonant Capital Advisors LLC now owns 4,177 shares of the medical research company’s stock worth $334,000 after purchasing an additional 373 shares during the period. United Asset Strategies Inc. lifted its holdings in shares of Edwards Lifesciences by 1.1% in the 1st quarter. United Asset Strategies Inc. now owns 193,864 shares of the medical research company’s stock worth $15,525,000 after purchasing an additional 2,119 shares in the last quarter. Burney Co. grew its position in Edwards Lifesciences by 12.7% in the 1st quarter. Burney Co. now owns 47,239 shares of the medical research company’s stock valued at $3,783,000 after purchasing an additional 5,337 shares during the period. Swedbank AB increased its stake in Edwards Lifesciences by 0.7% during the 1st quarter. Swedbank AB now owns 309,716 shares of the medical research company’s stock valued at $24,802,000 after purchasing an additional 2,153 shares in the last quarter. Finally, Shelton Wealth Management LLC acquired a new position in Edwards Lifesciences during the first quarter worth $1,077,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a research report on Wednesday, April 1st. BTIG Research lifted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Finally, Barclays reissued an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $97.09.

Insider Transactions at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,577 shares of company stock worth $3,855,527 in the last 90 days. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Up 1.0%

Shares of NYSE EW traded up $0.89 during trading on Friday, hitting $92.22. The stock had a trading volume of 3,381,397 shares, compared to its average volume of 4,354,287. The firm has a fifty day moving average of $86.73 and a two-hundred day moving average of $83.87. The company has a market capitalization of $53.10 billion, a PE ratio of 49.05, a PEG ratio of 2.29 and a beta of 0.86. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same period in the previous year, the company earned $0.64 earnings per share. The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.